remain overweight rate share rais dupix estim yet
base result new dermatologist survey indic extrem clinic satisfact
increas uptak robust project dupix interestingli posit feedback
come despit see somewhat lacklust commerci effort inde appear
money left tabl due signific reimburs challeng
inadequ patient direct market effort emin fixabl clinic
experi impress get continu like chanc upsid
far dupix live lofti expect beat estim last
two quarter achiev target prescrib base doc within first
two quarter launch reach last updat think fair say
one closely-scrutin drug launch biotech strong start
indic upsid continu herein discuss recent
dermatologist survey data partner spherix global insight think
suggest room upsid estim driven continu strong physician
dupix percept increas depth prescrib
cant say enough much doc love drug nearli year dupix
launch physician increasingli view major advanc ad treatment
classifi signific advanc compar eucrisa
project look strong patient per prescrib grew compar
one patient increas last quarter prescrib breadth alreadi high level
survey even derm captur view conserv user
biolog see key growth opportun go forward
lot money left tabl discontinu remain fairli low
half relat insur oop cost addit feedback point
sign commerci effort lot room improv doc indic
continu frustrat reimburs hurdl first us least doc
actual ask dtc campaign sooner rather later
trust said see barrier dupix use emin fixabl
regeneron/sanofi think underli clinic satisfact continu
drive increas use therefor rais estim consensu
commerci regulatori clinic ip risk associ market pipelin product
regeneron develop market therapi address varieti diseas
discount back
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
remain overweight rate share rais dupix estim yet base
result new dermatologist survey indic extrem clinic satisfact increas uptak
robust project dupix interestingli posit feedback come despit
see somewhat lacklust commerci effort inde appear lot money left
tabl due signific reimburs challeng inadequ patient-direct
market effort issu emin fixabl clinic experi
impress get continu like chanc upsid
continu see dupix launch one biotech wide anticip
heavili scrutin drug launch even post beat think
question whether forward expect achiev remain particularli histor
mix script data highlight im script data sinc dupix launch note
nrx appear plateau decemb januari recent updat
put posit trajectori measur achiev highest valu yet
recent week data end februari nrx though
continu watch trend sign continu growth plateau
survey
highlight note new survey data field partner spherix global insight
survey field januari meant gaug percept use pattern
project high-volum dermatologist elig particip survey
dermatologist practic two year manag least ad
patient spend least profession time clinic practic see patient spend
least profession time medic oppos cosmet dermatolog collect
sampl dermatologist treat ad patient address us adult atop
dermat popul estim
note differ survey popul compar derm
survey survey notabl sampl appear identifi
page
conserv use biolog survey derm classifi
conserv user biolog psoriasi identifi moder user describ
aggress biolog prescrib pso comparison
respond identifi conserv describ moder
aggress biolog prescrib pso see chart
respond biolog use psoriasi
doc realli love
shown figur ask much advanc dupix repres
treatment option ad physician consist indic signific advanc
fact percept improv sinc launch almost respond
consid signific advanc comparison doc view eucrisa
signific advanc survey compar base feedback
think fair say derm overwhelmingli appreci drug profil advanc
repres ad treatment
page
user base may
moder depth
back
question much advanc dupix current treatment option treatment atop dermat pleas use scale
advanc signific advanc
consid moder sever atop dermat popul much advanc dupix agent pleas use
scale advanc signific advanc
figur depict dupix user base among survey physician well averag
number prescript per physician per prescrib note numer
declin dupix user base use vs though view nois
survey describ earlier think one driver chang underli respond
popul recal describ conserv biolog prescrib pso
compar
even lower rel user base averag number patient dupix still
manag increas q/q perhap use metric
averag number patient therapi per prescrib grew almost patient q/q
repres faster growth saw last quarter
averag number dupix patient per user increas patient patient
find increas depth penetr encourag
page
dupix user base patient base first year launch
question mani total patient prescrib dupix
expand patient-bas also illustr figur show almost half
dupix user prescrib patient fulli two-third indic theyv prescrib
least four patient derm detail
dupix rep unsurprisingli prescrib drug frequent yet see
rep margin
page
question mani total patient prescrib dupix
driven
ask discontinu derm indic dupix patient
discontinu therapi compar survey dont think bad
howev somewhat concern us reason derm give discontinu
half driven either insur reason pocket cost patient
page
reason discontinu
depth like
question dupix patient mani subsequ discontinu
indic patient start dupix subsequ discontinu patient discontinu dupix
percent discontinu due
current dupix user anticip initi nearli new patient dupix next
quarter compar project initi non-us blend averag expect
dupix initi per doc next three month note derm
anticip eight dupix initi actual user ad dupix
patient given pretti common doc overestim futur patient add
launch would care take project face valu still dupix user
project similar patient add survey survey project
add think indic depth continu pick next quarter dynam
think bode well dupix revenu
page
dupix futur use candid therapi
question next three month mani new patient anticip place dupix
consid patient age age atop dermat follow sever categori percent consid candid dupix
red arrow indic project actual rate
still wood
highlight qualit feedback derm sanofi/regeneron dupix launch
divid three categori improv access/low cost market strategi
label expans includ adolesc children think main take-away taken
combin survey feedback detail earlier room commerci
organ step game reimburs hassl pocket cost remain huge
barrier prescrib one doc indic resolv willing prescrib would
skyrocket compani need resolv launch continu strong trajectori
feedback also highlight dtc campaign expect start year crucial
physician familiar drug grown hard us recal prior launch doc
actual ask dtc advertis unsurprisingli doc indic eager
approv patient alreadi work phase trial children on-going
phase adolesc data due follow potenti approv
page
advic sanofi/regeneron
question advic sanofi/regeneron introduc dupix market multipl respons record
given feedback think appropri rais estim near- mid-term
sign point continu increas depth penetr increas end-us
ww dupix revenu estim ahead consensu increas
page
access/costssamplesprovid sampl six month guarante access frontwork manag care contractsfind way get cover adult patient includ medicar patientsto make access patient appropri cost drugpleas help get med cover insur patient see wealthi patient good insur never seen drug wish prescrib get cover fix price fli shelvescost biggest issu administr burden huge thing medicin go prescrib person commit sever hour phone call paperwork could prescrib sanofi would rest far work insur perhap even negoti price individu basi insur compani willing prescrib would skyrocket anyon would avoid hassl refer onto academ center often somarketingstress efficacyhav strong dtc advertisementsdon give patient unreason expect push dermatolog officesstress novel treatment first safe system treatment ever itch stop immediatelywint season eczema flare market nowund approv quickli safe would like dose guidelin patient meantimego pediatr indicationotherkeep great research
estim also ahead consensu also make slight chang
expens estim net impact caus ep estim increas slightli
respect
old vs new piper estim factset consensu
page
good sold
product sale
collabor manufactur
collabor revenu
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
